New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
07:05 EDTISISIsis Pharmaceuticals initiates Phase 1 study of ISIS-ANGPTL3 Rx
Isis Pharmaceuticals nannounced that it has initiated a Phase 1 clinical study for ISIS-ANGPTL3 Rx, an antisense drug targeting angiopoietin-like 3 protein, an independent risk factor for cardiovascular disease. ISIS-ANGPTL3 Rx is designed to act as a broad dyslipidemia agent. By reducing ANGPTL3, ISIS-ANGPTL3 Rx has the potential to reduce LDL-cholesterol and triglycerides, and to increase insulin sensitivity. Isis plans to evaluate ISIS-ANGPTL3 Rx in patients who have severe metabolic or cardiovascular disease and who would benefit from a drug that simultaneously addresses a variety of adverse lipid and metabolic parameters contributing to their disease.
News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
07:05 EDTISISIsis Pharmaceuticals initiates ISIS-APOCIII Phase 3 study
Subscribe for More Information
August 22, 2014
12:39 EDTISISThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use